AMAG Pharmaceuticals Inc. Sets New 1-Year High at $25.91 (AMAG)
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) hit a new 52-week high on Wednesday, American Banking and Market News reports. The company traded as high as $25.91 and last traded at $25.68, with a volume of 20,360 shares trading hands. The stock had previously closed at $25.44.
A number of analysts have recently weighed in on AMAG shares. Analysts at Leerink Swann raised their price target on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from $23.00 to $25.00 in a research note to investors on Friday, August 2nd. Analysts at Jefferies Group raised their price target on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from $14.00 to $16.00 in a research note to investors on Friday, August 2nd. They now have an “underperform” rating on the stock.
AMAG Pharmaceuticals has a 52-week low of $13.85 and a 52-week high of $26.00. The stock has a 50-day moving average of $23.90 and a 200-day moving average of $22.45. The company’s market cap is $560.1 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings data on Thursday, August 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. The company had revenue of $19.60 million for the quarter, compared to the consensus estimate of $18.51 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was down 36.8% on a year-over-year basis. Analysts expect that AMAG Pharmaceuticals will post $-0.51 EPS for the current fiscal year.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.